lurtotecan has been researched along with Sarcoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baccanari, D; Bendele, R; Brown, E; Chiang, S; Desjardins, JP; Dihel, LC; Emerson, DL; Gill, SC; Hamilton, M; LeRay, JD; Luzzio, MJ; Moon-McDermott, L; Moynihan, K; Richardson, FC; Tomkinson, B | 1 |
1 other study(ies) available for lurtotecan and Sarcoma
Article | Year |
---|---|
Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Carbon Radioisotopes; Drug Carriers; Female; Humans; KB Cells; Liposomes; Mice; Mice, Nude; Sarcoma; Tissue Distribution; Topotecan; Xenograft Model Antitumor Assays | 2000 |